TG Therapeutics | TGTX - Gross Profit On Sales

Stock Price
30.35
Daily Change
-0.55 -1.78%
Monthly
0.13%
Yearly
0.86%
Q1 Forecast
28.61

TG Therapeutics reported $154.43M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Amgen USD 6.48B 307M Sep/2025
Ardelyx USD 106.35M 23.51M Sep/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
Bayer EUR 5.35B 1.02B Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
Corcept Therapeutics USD 199.58M 3.46M Dec/2025
Curis USD -7.72M 140K Jun/2024
Gilead Sciences USD 6.31B 106M Dec/2025
Infinity Pharmaceuticals USD 231K 59K Jun/2023
J&J USD 16.6B 118M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Novartis USD 10.82B 695M Sep/2025
Novavax USD 23.89M 239.21M Sep/2024
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
TG Therapeutics USD 154.43M 20.81M Dec/2025
Verastem USD 545K 543K Dec/2021
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025